The company dosed nine participants in its ONP-002 trial and received an FDA response regarding its IND application. It also flagged a potential NYSE American delisting due to a $4 million stockholders' equity deficiency.
The company dosed nine participants in its ONP-002 trial and received an FDA response regarding its IND application. It also flagged a potential NYSE American delisting due to a $4 million stockholders' equity deficiency.